IMAGES PROVIDED BY:
(1) Photo Courtesy of CDC
(2) Dr. Kenneth Greer/Visuals Unlimited
(3) SIU/Visuals Unlimited, Scott Camazine/Phototake
(4) Dr. P. Marazzi/Photo Researchers Inc
(5) Scott Camazine/Photo Researchers Inc
(6) Photo Alto/Eric Audras
(7) Christopher Furlong/Getty Images
(8) Pulse Picture Library/Phototake
(9) Odilon Dimier/PhotoAlto
(10) Robert Llewellyn/Workbook Stock
(11) Cappi Thompson/Flickr
(12) Hank Morgan/Photo Researchers Inc
(14) Steve Pomberg / WebMD
(16) DAJ, Thinkstock
49th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, Sept. 12-15, 2009.
American Academy of Dermatology web site.
American Academy of Family Physicians.
Andreas Sing, MD, Bavarian Food and Health Safety Authority, Germany.
Capriotti, T. Dermatology Nursing, Jan. 26, 2004.
Centers for Disease Control and Prevention web site.
FDA, FDA Approves Dalvance to Treat Skin Infections
Durata Therapeutics: FDA Approves Durata Therapeutics’ Dalvance for Treatment of Acute Bacterial Skin and Skin Structure (ABSSSI) Caused by Susceptible Gram-Positive Bacteria, Including MRSA, in Adults
Johnson, L. Infections in Medicine, 2005.
Kansas Journal of Medicine, 2008.
Kisgen, J.J., American Journal of Health System Pharmacy, April 2014. Tedizolid: a new oral antimicrobial
Lance Peterson, MD, department of microbiology and infectious diseases research, NorthShore University Health System, Evanston, Ill.
Liu, C. Clinical Infectious Diseases, January 2011.
Marilyn Roberts, PhD, department of environmental and occupational health sciences, University of Washington School of Public Health and Community Medicine, Seattle.
The Medicines Company: ORBACTIV™ (oritavancin) for injection
National Institute of Allergy and Infectious Diseases web site.
Nemours Foundation. Kids Health for Parents web site.
Sing, A. The New England Journal of Medicine, March 13, 2008.
The University of Chicao Medicine MRSA Research Center.
Up to Date web site.